109 related articles for article (PubMed ID: 12471575)
1. The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients.
Jensen-Fangel S; Pedersen L; Pedersen C; Larsen CS; Tauris P; Møller A; Sørensen HT; Obel N
Clin Infect Dis; 2002 Dec; 35(12):1541-8. PubMed ID: 12471575
[TBL] [Abstract][Full Text] [Related]
2. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
3. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
Lohse N; Kronborg G; Gerstoft J; Larsen CS; Pedersen G; Pedersen C; Sørensen HT; Obel N
Clin Infect Dis; 2006 Jan; 42(1):136-44. PubMed ID: 16323104
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes among antiretroviral-naive human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression.
Dronda F; Moreno S; Moreno A; Casado JL; Pérez-Elías MJ; Antela A
Clin Infect Dis; 2002 Oct; 35(8):1005-9. PubMed ID: 12355389
[TBL] [Abstract][Full Text] [Related]
5. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
6. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
Wong KH; Chan KC; Lee SS
Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
[TBL] [Abstract][Full Text] [Related]
7. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.
Rockstroh JK; Mocroft A; Soriano V; Tural C; Losso MH; Horban A; Kirk O; Phillips A; Ledergerber B; Lundgren J;
J Infect Dis; 2005 Sep; 192(6):992-1002. PubMed ID: 16107951
[TBL] [Abstract][Full Text] [Related]
8. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
[TBL] [Abstract][Full Text] [Related]
9. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease.
Hoffmann C; Chow KU; Wolf E; Faetkenheuer G; Stellbrink HJ; van Lunzen J; Jaeger H; Stoehr A; Plettenberg A; Wasmuth JC; Rockstroh J; Mosthaf F; Horst HA; Brodt HR
Br J Haematol; 2004 May; 125(4):455-62. PubMed ID: 15142115
[TBL] [Abstract][Full Text] [Related]
10. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
[TBL] [Abstract][Full Text] [Related]
11. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
Viani RM; Araneta MR; Deville JG; Spector SA
Clin Infect Dis; 2004 Sep; 39(5):725-31. PubMed ID: 15356789
[TBL] [Abstract][Full Text] [Related]
12. Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3.
Toulson AR; Harrigan R; Heath K; Yip B; Brumme ZL; Harris M; Hogg RS; Montaner JS
J Infect Dis; 2005 Nov; 192(10):1787-93. PubMed ID: 16235178
[TBL] [Abstract][Full Text] [Related]
13. Understanding the role of HIV load in determining weight change in the era of highly active antiretroviral therapy.
Mwamburi DM; Wilson IB; Jacobson DL; Spiegelman D; Gorbach SL; Knox TA; Wanke CA
Clin Infect Dis; 2005 Jan; 40(1):167-73. PubMed ID: 15614708
[TBL] [Abstract][Full Text] [Related]
14. Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study.
Dragsted UB; Mocroft A; Vella S; Viard JP; Hansen AB; Panos G; Mercey D; Machala L; Horban A; Lundgren JD;
J Infect Dis; 2004 Jul; 190(1):148-55. PubMed ID: 15195254
[TBL] [Abstract][Full Text] [Related]
15. Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network.
Chaix ML; Desquilbet L; Descamps D; Costagliola D; Deveau C; Galimand J; Goujard C; Signori-Schmuck A; Schneider V; Tamalet C; Pellegrin I; Wirden M; Masquelier B; Brun-Vezinet F; Rouzioux C; Meyer L; ;
Antivir Ther; 2007; 12(8):1305-10. PubMed ID: 18240870
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M
Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538
[TBL] [Abstract][Full Text] [Related]
17. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
[TBL] [Abstract][Full Text] [Related]
18. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
[TBL] [Abstract][Full Text] [Related]
19. The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens.
Maggiolo F; Ripamonti D; Torti C; Arici C; Antinori A; Quiros-Roldan E; Minoli L; Sighinolfi L; Nasta P; Suter F;
Antivir Ther; 2006; 11(7):923-9. PubMed ID: 17302255
[TBL] [Abstract][Full Text] [Related]
20. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
